Наследственные болезни национальное руководство бочков

Укажите регион, чтобы мы точнее рассчитали условия доставки

Начните вводить название города, страны, индекс, а мы подскажем

Например: 
Москва,
Санкт-Петербург,
Новосибирск,
Екатеринбург,
Нижний Новгород,
Краснодар,
Челябинск,
Кемерово,
Тюмень,
Красноярск,
Казань,
Пермь,
Ростов-на-Дону,
Самара,
Омск

616-056.7:575-07-08(035.3)
Н 31

    Наследственные болезни: национальное руководство : руководство / гл. ред. акад. рамн Н. П. Бочков ; акад. рамн: Е. К. Гинтер, В. П. Пузырев. — М. : Гэотар Медиа, 2012. — 936 с. — (АСМОК). — ISBN 978-5-9704-2231-1 : 10428.57 т.
Приложение:
Сопроводительный материал :CD-ROM №97 (эл. опт. диск (CD-ROM) Наследственные болезни: национальное руководство [Текст] : руководство / гл. ред. акад. рамн Н. П. Бочков ; акад. рамн: Е. К. Гинтер, В. П. Пузырев. — М. : Гэотар Медиа, 2012. — 936 с. — (АСМОК). — ISBN 978-5-9704-2231-1 : 10428.57 т.-НА)

УДК	616-056.7:575-07-08(035.3)

Рубрики: Наследственные болезни—руководство

Кл.слова (ненормированные):
ХРОМОСОМЫ — ОПУХОЛЬ — МУТАЦИЯ — СКРИНИНГ

Доп.точки доступа:
Бочков, Н. П. гл. ред. акад. рамн.
Гинтер, Е. К. акад. рамн.
Пузырев, В. П. акад. рамн.

Экземпляры всего: 1
НА (1)
Свободны: НА (1)

Также рекомендуем скачать

1. Health Departments of the United Kingdom Second Report of the UK National Screening Committee (2000)

2. Saudubray J, Matthias R. Baumgartner, John Walter (Eds.) Inborn Metabolic Diseases Diagnosis and Treatment 6th edition, Springer 2016, 658 с, ISBN 978-3-662-49769-2

3. Wilson JM, Jungner YG: Principles and practice of mass screening for disease. Geneva: WHO, 1968

4. Council of Europe. Recommendation No R(94)11 on screening as a tool of preventive medicine. 1994

5. Millington S., N. Kodo, D.L. Norwood, C.R. Roe Tandem mass spectrometry: A new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism J Inherit Metab Dis, 13 (1990), pp. 321-324

6. Tarini B.A., Christakis D.A and Welch HG State Newborn Screening in the Tandem Mass Spectrometry Era: More Tests, More False-Positive Results Pediatrics 2006;118;448

7. la Marca G, Malvagia S, Pasquini E, Innocenti M, Donati MA, Zammarchi E. Rapid 2nd-tier test for measurement of 3-OH-propionic and methylmalonic acids on dried blood spots: reducing the false-positive rate for propionylcarnitine during expanded newborn screening by liquid chromatography-tandem mass spectrometry.Clin Chem. 2007 Jul;53(7):1364-9.

8. Janzen N, Terhardt M, Sander S, Demirkol M, Gцkзay G, Peter M, Lьcke T, Sander J, Das AM Towards newborn screening for ornithine transcarbamylase deficiency: fast non-chromatographic orotic acid quantification from dried blood spots by tandem mass spectrometry.Clin Chim Acta. 2014 Mar 20;430:28-32.

9. Gu X, Wang Z, Ye J, Han L, Qiu W. Newborn screening in China: Phenylketonuria, congenital hypothyroidism and expanded screening. Ann Acad Med Singapore. 2008;37(12 Suppl):107-4. (51)

10. Niu DM, Chien YH, Chiang CC, Ho HC, Hwu WL, Kao SM, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. J Inherit Metab Dis. 2010;33(Suppl 2):S295-305. (52)

11. Yoon HR, Lee KR, Kim H, Kang S, Ha Y, Lee DH. Tandem mass spectrometric analysis for disorders in amino, organic and fatty acid metabolism: Two year experience in South Korea. Southeast Asian J Trop Med Public Health. 2003;34(Suppl 3):115-20 (53)

12. Yamaguchi S. Newborn screening in Japan: Restructuring for the new era. Ann Acad Med Singapore. 2008;37(12 Suppl):13-5. (54)

13. Lund AM, Hougaard DM, Simonsen H, Andresen BS, Christensen M, Duno M, et al. Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland — Experience and development of a routine program for expanded newborn screening. Mol Genet Metab. 2012;107:281-93. (55)

14. Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: A two-year summary from the New England Newborn Screening Program. Clin Chem. 2001;47:1945-55. (56)

15. Chace DH, Kalas TA, Naylor EW. The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism. Annu Rev Genomics Hum Genet. 2002;3:17-45. (57)

16. Lindner M, Abdoh G, Fang-Hoffmann J, Shabeck N, Al-Sayrafi M, Al-Janahi M, et al. Implementation of extended neonatal screening and a metabolic unit in the State of Qatar: Developing and optimizing strategies in cooperation with the Neonatal Screening Center in Heidelberg. J Inherit Metab Dis. 2007;30:522-9. (20)

17. Lee HC, Mak CM, Lam CW, Yuen YP, Chan AO, Shek CC, et al. Analysis of inborn errors of metabolism: Disease spectrum for expanded newborn screening in Hong Kong. Chin Med J (Engl) 2011;124:983-9. (21)

18. Gelb MH, Turecek F, Scott CR, et al. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis. 2006;29:397-404

19. Lisi E.C., McCandless S.E. Newborn screening for lysosomal storage disorders: Views of genetic healthcare providers J Genet Couns, 25 (2016), pp. 373-384.,

20. Matern D., Gavrilov D., Oglesbee D., et al.Newborn screening for lysosomal storage disorders Semin Perinatol, 39 (2015), pp. 206-216

21. Spada M, Pagliardini S, Yasuda M, Turkel T, Thiagarajan G, Sakuraba H, et al. Incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31-40

22. Kwon JM, Levy PA, Miller-Horn J, Naidich TP, Pellegrino JE, Provenzale JM, et al. Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol. 2009;40(4):245-252.

23. Orsini JJ, Morrissey NA, Slavin LN, Wojcik M, Biski C, Martin M, et al. Implementation of newborn screening for Krabbe disease: population study and cut off determination. Clin Biochem. 2009;42:877-884

24. Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics. 2009;124:e1116-e1125.

25. Hwu WL, Chien YH, Lee NC, Dobrovolny R, Huang AC, Yeh HY, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c. 9361919G4A (IVS41919G4A) Hum Mut. 2009;30:1397-1405.

26. Wittmann J, Karg E, Turi S, et al. Newborn Screening for Lysosomal Storage Disorders in Hungary JIMD Rep. 2012; 6: 117-125.

27. Scott CR, Elliott S, Spacil Z, et al. A pilot program screening for Fabry, Pompe, and MPS I in a newborn screening laboratory: the first 60,000 samples. Mol Genet Metab. 2012;2:S56-S57.

28. Thomas, P., Susanne, S., Thomas, F., Vнctor, R., Susanne, G., Arnold, P. et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 379, 335-341 (2012).

29. Scott CR, Elliott S, Buroker N, et al. Identification of infants at risk for developing Fabry, Pompe or Mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. The Journal of pediatrics. 2013;163(2):498-503.

30. Lin HY, Chong KW, Hsu JH, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ CardiovascGenet. 2009;2:450-456.

31. Kemper AR, Knapp AA, Green NS, et al. Weighing the evidence for newborn screening for early infantile Krabbe disease. Gen Med. 2010;12:539-43

32. Howard HC, Knoppers BM, Cornel MC, et al. Whole-genome sequencing in newborn screening? A statement on the continued importance of targeted approaches in newborn screening programmes. European Journal of Human Genetics. 2015;23(12):1593-1600.

33. Friedman JM, Cornel MC, Goldenberg AJ, et al. Genomic newborn screening: public health policy considerations and recommendations. BMC Medical Genomics. 2017;10:9.

34. Middha S, Lindor NM, McDonnell SK, Olson JE, Johnson KJ, Wieben ED, et al. How well do whole exome sequencing results correlate with medical findings? A study of 89 Mayo Clinic Biobank samples. Front Genet. 2015;6:244.

35. Frebourg T. The challenge for the next generation of medical geneticists. Hum Mutat. 2014;35:909-911

36. American Academy of Pediatrics, Newborn Screening Task Force. (2000) Serving the family from birth to the medical home: newborn screening a blueprint for the future. Pediatrics 106:389-427

37. Watson MS, Mann MY, Lloyd-Puryear MA, Rinaldo P, HowellRR [editors]. (2006) Newborn screening: Toward a uniformscreening panel and system [Executive summary]. Genet Med8(Supplement):1S-11S.,

38. Watson MS, Lloyd-Puryear MA, Mann MY, Rinaldo P, HowellRR [editors]. (2006) Newborn screening: Toward a uniform screening panel and system [Main report]. Genet Med 8 (Supplement):12S-252S

39. Chace DH, Kalas TA, Naylor EW. 2003. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 49:1797-1817

40. Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJ, Adams J.Semin Perinatol. 2015 Apr;39(3):171-87. Current status of newborn screening worldwide: 2015.

41. Дерябина C.C. Неонатальный скрининг: этические вопросы расширения спектра скринируемых заболеваний. Вопросы современной педиатрии. 2015;14(6):714-723.).

42. Beth A. Tarini, Dimitri A. Christakis, H. Gilbert Welch State Newborn Screening in the Tandem Mass Spectrometry Era: More Tests, More False-Positive Results Pediatrics Aug 2006, 118 (2) 448-456;

43. Prosser LA, Ladapo JA, Rusinak D, Waisbren SE: Parental tolerance of false-positive newborn screening results. Arch Pediatr Adolesc Med. 2008, 162 (9): 870-876.

44. Howell R. The high price of false positives. Mol Genet Metab 2006;87:180-3.

45. Наследственные болезни: национальное руководство / под ред. Акад. РАМН Н.П. Бочкова, акад. РАМН Е.К. Гинтера, акад РАМН В.П. Пузырева. — М/: ГЭОТАР-медиа, 2012. — с.888-927

46. Tarini BA, Burke W, Scott CR, Wilfond BS. Waiving informed consent in newborn screening research: balancing social value and respect. Am J Med Genet C Semin Med Genet. 2008;148C:23-30.

47. Hall PL, Marquardt G, McHugh DMS, et al. Postanalytical tools improve performance of newborn screening by tandem mass spectrometry. Genetics in Medicine. 2014;16(12):889-895.

48. De Jesus VR, Mei JV, Cordovado SK, Cuthbert CD. The Newborn Screening Quality Assurance Program at the Centers for Disease Control and Prevention: Thirty-five Year Experience Assuring Newborn Screening Laboratory Quality. International journal of neonatal screening. 2015;1(1):13-26.

49. Martinez-Morillo E, Prieto Garcia B, Alvarez Menendez FV Challenges for Worldwide Harmonization of Newborn Screening Programs. Clin Chem. 2016 May;62(5):689-98.